Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction
- PMID: 15219500
- DOI: 10.1016/j.amjcard.2004.03.021
Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction
Abstract
Despite early recanalization of an occluded infarct artery, up to 33% of patients with acute myocardial infarction do not obtain complete myocardial reperfusion due to a process of reperfusion injury. This study assessed whether adjunctive therapy with adenosine might prevent or attenuate the phenomenon of myocardial reperfusion injury. Myocardial reperfusion was assessed in 79 consecutive patients receiving a 20-minute intracoronary infusion of adenosine during percutaneous coronary intervention (PCI) and in a historical cohort of 200 patients with acute myocardial infarction who were treated with PCI (controls). Myocardial reperfusion injury was defined as persistent (> or =50% of initial value) ST-segment elevation after successful recanalization. Its effect on infarct size was evaluated by calculating the Selvester QRS score before intervention and at follow-up. Myocardial reperfusion injury was present in 19% of patients receiving adenosine versus 35% of control patients (p = 0.004). Evaluation of infarct expansion over time showed almost no change in the QRS score in patients receiving adenosine (3.4 +/- 3.0 before PCI; 3.5 +/- 3.1 at follow-up). In contrast, infarct QRS score in the control group worsened from 3.1 +/- 2.7 before PCI to 4.5 +/- 3.2 at follow-up (p = 0.003 treatment with adenosine vs control). Multivariate analysis identified adjunctive therapy with adenosine as an independent protective determinant of myocardial reperfusion injury and of infarct expansion. The rate of major adverse cardiac events (death and myocardial infarction) at 1 month tended to be lower in patients receiving adenosine (4% vs 6.5%, p = 0.7) and was mainly observed in patients with evidence of myocardial reperfusion injury (cardiac event rate 2% in patients with ST-segment elevation of <50% vs 14% in patients with ST-segment elevation > or =50%, p = 0.003). Thus, impaired myocardial reperfusion is the most important determinant of clinical outcome in patients with acute myocardial infarction treated with PCI. Adjunctive therapy with intracoronary infusion of adenosine during PCI prevents the occurrence of severe myocardial reperfusion injury and is associated with less infarct expansion.
Similar articles
-
New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.Am J Cardiol. 2011 Apr 15;107(8):1131-5. doi: 10.1016/j.amjcard.2010.12.010. Am J Cardiol. 2011. PMID: 21310372 Clinical Trial.
-
Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098442 Clinical Trial.
-
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.Circ Cardiovasc Interv. 2009 Aug;2(4):323-9. doi: 10.1161/CIRCINTERVENTIONS.109.858977.109.858977. Epub 2009 Jul 22. Circ Cardiovasc Interv. 2009. PMID: 20031735 Clinical Trial.
-
Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Ther Adv Cardiovasc Dis. 2012 Jun;6(3):101-14. doi: 10.1177/1753944712446670. Epub 2012 May 4. Ther Adv Cardiovasc Dis. 2012. PMID: 22562999 Review.
-
Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.Am J Cardiovasc Drugs. 2004;4(3):159-67. doi: 10.2165/00129784-200404030-00003. Am J Cardiovasc Drugs. 2004. PMID: 15134468 Review.
Cited by
-
Myocardial preservation during primary percutaneous intervention: It's time to rethink?Indian Heart J. 2021 Jul-Aug;73(4):395-403. doi: 10.1016/j.ihj.2021.07.008. Epub 2021 Jul 28. Indian Heart J. 2021. PMID: 34474749 Free PMC article. No abstract available.
-
Evaluation of Short- and Long-Term Efficacy of Combined Intracoronary Administration of High-Dose Adenosine and Tirofiban during Primary Percutaneous Coronary Intervention.Acta Cardiol Sin. 2016 Nov;32(6):640-648. doi: 10.6515/acs20151013i. Acta Cardiol Sin. 2016. PMID: 27899850 Free PMC article.
-
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.Trials. 2014 May 1;15:151. doi: 10.1186/1745-6215-15-151. Trials. 2014. PMID: 24885437 Free PMC article. Clinical Trial.
-
A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction.Ann Transl Med. 2021 Jan;9(2):126. doi: 10.21037/atm-20-8003. Ann Transl Med. 2021. PMID: 33569428 Free PMC article.
-
Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice.Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2322-33. doi: 10.1152/ajpheart.00052.2011. Epub 2011 Sep 23. Am J Physiol Heart Circ Physiol. 2011. PMID: 21949117 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous